A Drug Withdrawal Has Accidentally Opened the Door to Cheaper, Broader Treatment on the PBS
The body that advises the federal government on subsidised medicines has recommended triptorelin be funded for breast cancer, endometriosis and gender dysphoria, making it available across all uses on the Pharmaceutical Benefits Scheme (PBS). The Guardian
The Pharmaceutical Benefits Advisory Committee (PBAC) — the independent expert panel that tells government which drugs should be subsidised — held an urgent meeting in July 2026. The trigger was AstraZeneca's decision to pull Zoladex (goserelin) from the Australian market, which threatened to leave more than 7,500 women with breast cancer without a subsidised alternative. Both Zoladex and triptorelin are gonadotropin-releasing hormone (GnRH) agonists: drugs that suppress the release of oestrogen and testosterone. Both are listed as essential medicines by the World Health Organization.
Triptorelin has been PBS-listed for prostate cancer since 2006. The RACGP reported in late July that the drug is also used for women's health conditions — mainly breast cancer, endometriosis and fibroids — but had not been PBS-subsidised for those indications. RACGP
The PBAC's public summary documents from the July meeting specifically backed triptorelin (Diphereline) 3.75 mg for breast cancer as a subsidised monthly treatment. Breast Cancer Network Australia The committee also recommended a review of prescribing patterns around two years after any PBS listing change. RACGP
By recommending triptorelin be listed as "unrestricted" — meaning funded for all uses, not just specific conditions — the PBAC has positioned the drug to fill the gap left by Zoladex across every indication, not only breast cancer. The practical effect for patients is substantial. Fiona Bisshop, a Brisbane GP at Stonewall Medical Centre, said a PBS listing would cut the cost of private prescribing from about $3,000 a year to about $300, or roughly $25 a week.
If the federal government acts on the recommendation, gender-affirming care would be funded through the PBS for the first time. That is a notable threshold to cross, and it lands in a political landscape where gender-affirming treatment for minors has been contested at the state level. In January 2025 the Queensland government banned public hospitals from prescribing gender-affirming drugs to transgender children, affecting more than 491 patients on the state gender clinic's waitlist. Queensland's Supreme Court overturned the ban, but the government immediately reimposed it. The Northern Territory subsequently imposed a comparable restriction on public hospital prescribing for transgender children.
Those state-level bans operate in a different jurisdictional lane from the PBS, which is a Commonwealth program. A federal decision to subsidise triptorelin for gender dysphoria would not override a state ban on public hospital prescribing. What it would do is materially lower the cost barrier for patients who access treatment through private prescribing pathways, which remain legal in those jurisdictions. Bisshop's cost figures give a sense of the scale: a tenfold reduction in annual out-of-pocket cost is not marginal.
The broader context here is a supply-driven policy response that has produced a wider outcome than the triggering event alone required. AstraZeneca's withdrawal of Zoladex created an acute gap for breast cancer patients. The PBAC's recommendation addresses that gap, but by backing an unrestricted listing it has also extended subsidised access to endometriosis and gender dysphoria. Whether the federal government implements the recommendation in full, and on what timeline, will determine whether that expanded access materialises. The committee's suggestion of a two-year utilisation review signals an expectation that prescribing patterns will be monitored once the listing takes effect.
For breast cancer patients, the urgency is clear. More than 7,500 women faced the loss of a subsidised treatment option through no fault of clinical practice or policy design, but through a commercial decision by a manufacturer. The PBAC's urgent July meeting and the speed of its recommendation reflect that pressure. For endometriosis and gender dysphoria patients, the recommendation opens a different kind of opportunity: access to a subsidised GnRH agonist where none previously existed on the PBS.
The PBS Schedule has listed triptorelin embonate as a powder for intramuscular injection for breast cancer treatment as part of a chemotherapy cycle dating back to at least April 2010, per published PBS records. PBS The PBAC's public summary documents, indexed by drug name and meeting date on the PBS website, provide the full record of the committee's considerations. PBS
What remains is the government's decision. The PBAC recommends; the Minister for Health and Aged Care and Cabinet decide whether to list. That is the next step, and everything from patient costs to the precedent of federally subsidised gender-affirming care hinges on it.
